ABL Bio Inc
298380
Company Profile
Business description
ABL Bio Inc is a Korean biotech research company. The company is engaged in the development of therapeutic drugs for immuno-oncology and neurodegenerative diseases. Its pipeline products include ABL001 an Bispecific Antibody, ABL201-205 an Antibody Drug Conjugate, T cell engager, Dual Immune Cell Targeting BsAb an Immuno-Oncology, ABL301 an BBB-Penetrating Bispecific Antibody.
Contact
2nd Floor, 16 Daewangpangyo-Ro 712
Beon-Gil, Bundang-Gu
Gyeonggi-do
Seongnam-si13488
KORT: +82 3180189800
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
105
Stocks News & Analysis
stocks
Chart of the Week: Has gold reached bear market territory?
Investors are facing a shifting landscape.
stocks
Fair value upgrade for this ASX income player
Headwinds in listed energy stocks likely to have passed
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,885.60 | 59.90 | 0.68% |
| CAC 40 | 7,961.80 | 144.86 | 1.85% |
| DAX 40 | 23,190.98 | 510.94 | 2.25% |
| Dow JONES (US) | 46,341.51 | 1,125.37 | 2.49% |
| FTSE 100 | 10,369.23 | 192.78 | 1.89% |
| HKSE | 25,294.03 | 505.89 | 2.04% |
| NASDAQ | 21,590.63 | 795.99 | 3.83% |
| Nikkei 225 | 53,739.68 | 2,675.96 | 5.24% |
| NZX 50 Index | 12,825.87 | 86.24 | -0.67% |
| S&P 500 | 6,528.52 | 184.80 | 2.91% |
| S&P/ASX 200 | 8,671.80 | 53.10 | 0.62% |
| SSE Composite Index | 3,948.55 | 56.69 | 1.46% |